CuriRx Launches CuriLytics® Platform to Provide CMC Analytical Services to Support Complex Biotherapeutic Development Using High Resolution Mass Spectrometry
CuriRx Launches the Advanced Bioprocessing and Analytical Center to Support Biotherapeutic Drug Developers
Join CuriRx for a complimentary lunch & learn about our CuriLytics® platform!
CuriLytics®: De-risking CMC characterization
by using high-resolution mass spectrometry
Date: Tuesday, November 9th, 2021
Time: 12:00-1:00 pm
Place: MassBio Hub
700 Technology Square, 4th Floor
Cambridge, MA 02139
Reserve your seat now
Improving and de-risking the overall drug development path from Phase I clinical trials to approval requires advanced analytical assessment of critical quality attributes. Modern biopharmaceutical drugs, such as recombinant proteins, monoclonal antibodies (mAb), bispecific antibodies, vaccines, antibody-drug conjugates (ADCs), oligonucleotides and Gene therapy (AAV’s) are very complex molecules. Characterizing and monitoring these compounds for Chemistry, Manufacturing, and Controls (CMC) and other quality control environments can present a significant challenge. 
At this Lunch & Learn, Jon DeGnore, Associate Director of Analytical Development at CuriRx, will discuss the use of high-resolution accurate-mass mass spectrometry (HRAM-MS), offering a powerful way of overcoming these challenges. Chromatographic separation combined with the sensitivity and specificity of Orbitrap mass spectrometry yields greater insight into critical quality attributes that can be combined with a battery of orthogonal characterization methods to understand drug products better. HRAM-MS provides direct measurement of critical quality attributes of protein candidates at the individual residue level for a detailed understanding of how changes in process or production affect a drug product.
Case studies will be discussed.
